Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 440-446

  Bayliss, George ^a,b   Weinrauch, Larry A ^c   D'Elia, John A ^c,d  

^a MIRIAM HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adipocyte; Diabetes; Diabetic nephropathy; Insulin resistance; Nephrin; Obesity; Obstructive sleep apnea; Podocyte; Proteinuria; Renal dysfunction

Indexed keywords

ADIPONECTIN; CYTOKINE; FETUIN A; LEPTIN; MESSENGER RNA; NEPHRIN; RESISTIN;

BODY MASS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE REPRESSION; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HORMONAL REGULATION; HUMAN; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY INJURY; NEPHRIN GENE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PODOCYTE; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SLEEP APNEA SYNDROME;

ADIPONECTIN; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KIDNEY; LEPTIN; MALE; MEMBRANE PROTEINS; OBESITY; PODOCYTES; RESISTIN; SIGNAL TRANSDUCTION; SLEEP APNEA, OBSTRUCTIVE;

EID: 84865593922     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0288-1     Document Type: Review

References (42)

1. Preble WE. Obesity: Observation on one thousand cases. Boston Med Surg J. 1923;188:617-21.
2. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: A complication of massive obesity. Ann Intern Med. 1974;81:440-7.
3. Cohen AH. Massive obesity and the kidney. A morphologic and statistical study. Am J Pathol. 1975;81:117-30.
4. Verani RR. Obesity-associated focal segmental glomerulosclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992;20:629-34. (Pubitemid 23031716)
5. Kambham N, Markowitz GS, Valeri AM, et al. VD. Obesityrelated glomerulopathy: An emerging epidemic. Kidney Int. 2001;59:1498-509.
6. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-50. (Pubitemid 38543772)
7. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319-27. (Pubitemid 36152449)
8. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291:2013-6. (Pubitemid 38544284)
9. Chaudhary BA, Sklar AH, Chaudhary TK, et al. Sleep apnea, proteinuria, and nephrotic syndrome. Sleep. 1988;11:69-74.
10. Sklar AH, Chaudhary BA. Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med. 1988;148:87-9. (Pubitemid 18071384)
11. Sklar AH, Chaudhary BA, Harp R. Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron. 1989;51:35-8. (Pubitemid 19001756)
12. Tsioufis C, Thomopoulos C, Dimitriadis K, et al. Association of obstructive sleep apnea with urinary albumin excretion in essential hypertension: A cross-sectional study. Am J Kidney Dis. 2008;52:285-93. (Pubitemid 351978143)
13. Casserly LF, Chow N, Ali S, et al. Proteinuria in obstructive sleep apnea. Kidney Int. 2001;60:1484-9. (Pubitemid 32960043)
14. Chou YT, Lee PH, Yang CT, et al. Obstructive sleep apnea: A stand-alone risk factor for chronic kidney disease. Nephrol Dial Transplant. 2011;26:2244-50. This article discusses the relationship of sleep apnea, insulin resistance and proteinuria.
15. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10:49S-55S. (Pubitemid 27239831)
16. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Ren Physiol. 2000;278:F817-22. (Pubitemid 30351084)
17. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol: JASN. 2003;14:1480-6. (Pubitemid 36687049)
18. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: Its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23:3946-52.
19. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol: JASN. 2010;21:406-12.
20. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3:e1765.
21. Ix JH, Shlipak MG, Brandenburg VM, et al. Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation. 2006;113:1760-7. (Pubitemid 43958469)
22. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: The Rancho Bernardo study. Am J Epidemiol. 2007;165:164-74. (Pubitemid 46096378)
23. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645-56. (Pubitemid 351632369)
24. Baumann M, von Eynatten M, Dan L, et al. Altered molecular weight forms of adiponectin in hypertension. J Clin Hypertens. 2009;11:11-6.
25. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98:1603-8. (Pubitemid 44827969)
26. Pineiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005;579:5163-9. (Pubitemid 41318086)
27. Saginova EA, Galliamov MG, Severova MM, et al. The role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patients. Ter Arkh. 2011;83:47-53.
28. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50:708-14. (Pubitemid 47442735)
29. Coward R, Walsh GI, Koziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56:1127-35. (Pubitemid 46525068)
30. Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature. 2006;440:818-23.
31. Fornoni A, Jeon J, Varona Santos J, et al. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin releases. Diabetes. 2010;59:190-9. This article discusses the role of nephrin, an important glomerular protein, in secretion of insulin vessicles in the pancreas.
32. Hussain S, Romio L, Saleem M, et al. Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol: JASN. 2009;20:1733-43.
33. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors. J Am Soc Nephrol: JASN. 2006;17:3438-46. (Pubitemid 44865286)
34. Sharma R, Sharma M, Reddy S, et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci. 2006;11:968-76. (Pubitemid 43253451)
35. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773-9. (Pubitemid 40418380)
36. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-6. (Pubitemid 37499216)
37. Goodfriend TL, Ball DL, Egan BM, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-63. (Pubitemid 38174139)
38. Fliser D, Schaefer F, Schmid D, et al. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension. 1997;30:1156-61. (Pubitemid 27476173)
39. Blanco S, Bonet J, Lopez D, et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl. 2005;93:S10-4. (Pubitemid 40019208)
40. Saitoh Y, Hongwei W, Ueno H, et al. Telmisartan attenuates fattyacid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab. 2009;35:392-7.
41. Habibi J, Hayden MR, Sowers JR, et al. Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology. 2011;152:659-68. This article describes a possible nonhemodynamic mechanism by which a non-specific beta blocker may inhibit proteinuria.
42. Ahima RS. Linking adiponectin to proteinuria. J Clin Invest. 2008;118(5):1619-22. (Pubitemid 351632364)